Evidence map›Paper›PMID 39207757›Full record

ArticleJAMA network open2024

Change in Depressive Symptoms and Longitudinal Regional Amyloid Accumulation in Unimpaired Older Adults.

Catherine E Munro, Michelle Farrell, Bernard Hanseeuw, Dorene M Rentz, Rachel Buckley, Michael Properzi, Ziwen Yuan, Patrizia Vannini, Rebecca E Amariglio, Yakeel T Quiroz and 5 more

Abstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Depressive symptom instability predicts incident mild cognitive impairment and dementia in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Review
  4. Trajectories of late-life depression: insights from molecular imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  5. Neuromodulation and cognition in late-life depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  6. Article
  7. Article
  8. The influence of depression onset timing after gastrointestinal diseases on dementia risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Catherine E MunroBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Michelle FarrellMassachusetts General Hospital, Harvard Medical School, Boston.
Bernard HanseeuwMassachusetts General Hospital, Harvard Medical School, Boston.
Dorene M RentzBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Rachel BuckleyMassachusetts General Hospital, Harvard Medical School, Boston.
Michael ProperziMassachusetts General Hospital, Harvard Medical School, Boston.
Ziwen YuanMassachusetts General Hospital, Harvard Medical School, Boston.
Patrizia VanniniBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Rebecca E AmariglioBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Yakeel T QuirozMassachusetts General Hospital, Harvard Medical School, Boston.
Deborah BlackerMassachusetts General Hospital, Harvard Medical School, Boston.
Reisa A SperlingBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Keith A JohnsonBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Gad A MarshallBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Jennifer R GatchelMassachusetts General Hospital, Harvard Medical School, Boston.

Funding

Vascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley, Keith A. Johnson · 2010 to 2026
$50.2M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
ARMADA: Advancing Reliable Measurement in Alzheimer's Disease and cognitive Aging - Tech CoreU2CAG057441 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GERSHON, RICHARD, WEINTRAUB, SANDRA · 2017 to 2019
$10.8M
Novel automated performance-based ADL outcomes for early AD clinical trialsR01AG053184 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI MARSHALL, GAD ASHER · 2018 to 2023
$4.5M
Decoding neural systems underlying anosognosia for memory loss in aging and Alzheimer's diseaseR01AG061083 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI VANNINI, PATRIZIA · 2019 to 2023
$4.3M
Depression and Alzheimer's Disease: CaTAUstrophy?R01AG078191 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Jennifer Rose Gatchel · 2022 to 2026
$4.0M
Building predictive algorithms to identify resilience and resistance to Alzheimer's diseaseR01AG079142 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley, Michael C Donohue · 2023 to 2026
$4.0M
Characterizing the evolution of Subjective Cognitive Decline in preclinical Alzheimer's diseaseR01AG058825 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AMARIGLIO, REBECCA E · 2019 to 2024
$4.0M
Relationship between tau pathology and cognitive impairment in autosomal dominant Alzheimer's diseaseR01AG054671 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2017 to 2021
$3.8M
Neural Correlates of Apathy Across the Alzheimer's Disease ContinuumR01AG067021 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI MARSHALL, GAD ASHER · 2020 to 2025
$3.6M
The inactive X: discovering sex genes that influence female vulnerability to Alzheimer's diseaseDP2AG082342 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley · 2022 to 2026
$2.5M
Nerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's diseaseRF1AG077627 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI AGUILLON, DAVID FERNANDO, CUELLO, A CLAUDIO · 2022 to 2022
$2.0M
NIA NIH HHS DP2 AG082342NIA NIH HHS K01 AG083062NIA NIH HHS K23 AG058805NIA NIH HHS K24 AG035007NIA NIH HHS P01 AG036694NIA NIH HHS P30 AG062421NIA NIH HHS R00 AG061238NIA NIH HHS R01 AG053184NIA NIH HHS R01 AG054671NIA NIH HHS R01 AG058825NIA NIH HHS R01 AG061083NIA NIH HHS R01 AG067021NIA NIH HHS R01 AG078191NIA NIH HHS R01 AG079142NIA NIH HHS RF1 AG077627NIA NIH HHS U2C AG057441
6 · The paper itself

Abstract

Importance: Depressive symptoms in older adults may be a harbinger of Alzheimer disease (AD), even in preclinical stages. It is unclear whether worsening depressive symptoms are manifestations of regional distributions of core AD pathology (amyloid) and whether cognitive changes affect this relationship. Objective: To evaluate whether increasing depressive symptoms are associated with amyloid accumulation in brain regions important for emotional regulation and whether those associations vary by cognitive performance. Design, Setting, and Participants: Participants from the Harvard Aging Brain Study, a longitudinal cohort study, underwent annual assessments of depressive symptoms and cognition alongside cortical amyloid positron emission tomography (PET) imaging at baseline and every 2 to 3 years thereafter (mean [SD] follow-up, 8.6 [2.2] years). Data collection was conducted from September 2010 to October 2022 in a convenience sample of community-dwelling older adults who were cognitively unimpaired with, at most, mild baseline depression. Data were analyzed from October 2022 to December 2023. Main Outcomes and Measures: Depression (Geriatric Depression Scale [GDS]-30-item), cognition (Preclinical Alzheimer Cognitive Composite-5 [PACC]), and a continuous measure of cerebral amyloid (Pittsburgh compound B [PiB] PET) examined in a priori-defined regions (medial orbitofrontal cortex [mOFC], lateral orbitofrontal cortex, middle frontal cortex [MFC], superior frontal cortex, anterior cingulate cortex, isthmus cingulate cortex [IC], posterior cingulate cortex, and amygdala). Associations between longitudinal GDS scores, regional amyloid slopes, and PACC slopes were assessed using linear mixed-effects models. Results: In this sample of 154 individuals (94 [61%] female; mean [SD] age, 72.6 [6.4] years; mean (SD) education, 15.9 [3.1] years), increasing PiB slopes in the bilateral mOFC, IC, and MFC were associated with increasing GDS scores (mOFC: β = 11.07 [95% CI, 5.26-16.87]; t = 3.74 [SE, 2.96]; P = .004; IC: β = 12.83 [95% CI, 5.68-19.98]; t = 3.51 [SE, 3.65]; P = .004; MFC: β = 9.22 [95% CI, 2.25-16.20]; t = 2.59 [SE, 3.56]; P = .03). Even with PACC slope as an additional covariate, associations remained significant in these regions. Conclusions and Relevance: In this cohort study of cognitively unimpaired older adults with, at most, mild baseline depressive symptoms, greater depressive symptoms over time were associated with amyloid accumulation in regions associated with emotional control. Furthermore, these associations persisted in most regions independent of cognitive changes. These results shed light on the neurobiology of depressive symptoms in older individuals and underscore the importance of monitoring for elevated mood symptoms early in AD.

Indexed as

DepressionPositron-Emission TomographyAgedAged, 80 and overAlzheimer DiseaseAmyloidBrainCognitionFemaleHumansLongitudinal StudiesMaleAmyloid

Identifiers

PMID39207757
PMCPMC11362871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.